Cargando…

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial

BACKGROUND: LUX-Lung 8 was a randomised, controlled, phase 3 study comparing afatinib and erlotinib as second-line treatment of patients with advanced squamous cell carcinoma (SCC) of the lung. We report the final overall survival (OS) and safety analyses of LUX-Lung 8 and investigate the characteri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goss, Glenwood D, Cobo, Manuel, Lu, Shun, Syrigos, Konstantinos, Lee, Ki Hyeong, Göker, Erdem, Georgoulias, Vassilis, Isla, Dolores, Morabito, Alessandro, Min, Young J, Ardizzoni, Andrea, Bender, Shaun, Cseh, Agnieszka, Felip, Enriqueta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225678/ https://www.ncbi.nlm.nih.gov/pubmed/34195574 http://dx.doi.org/10.1016/j.eclinm.2021.100940

Ejemplares similares

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
por: Schuler, M., et al.
Publicado: (2016)

Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung
por: Lu, Shun, et al.
Publicado: (2018)

Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer
por: Isla, Dolores, et al.
Publicado: (2016)

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
por: Kim, Youjin, et al.
Publicado: (2019)

Synergistic Effect of Afatinib with Su11274 in Non-Small Cell Lung Cancer Cells Resistant to Gefitinib or Erlotinib
por: Chen, Gang, et al.
Publicado: (2013)

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
por: Schuler, Martin, et al.
Publicado: (2019)

A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer
por: Fujiwara, Atsushi, et al.
Publicado: (2018)

Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment
por: Choi, Hayoung, et al.
Publicado: (2021)

Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer
por: Howe, Grant A., et al.
Publicado: (2016)

Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)
por: Wu, Yi-Long, et al.
Publicado: (2017)

Rapid Response to High-Dose, Pulsatile Erlotinib in Afatinib-Refractory Leptomeningeal Carcinomatosis from Adenocarcinoma of the Lung: A Case Report
por: Fan, Frank S.
Publicado: (2016)

Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3
por: Kato, Terufumi, et al.
Publicado: (2015)

Effect of Dose Adjustments on the Safety and Efficacy of Afatinib in Chinese Patients with EGFR-Mutated Non-Small Cell Lung Cancer Who Participated in the LUX-Lung Clinical Trial Program
por: Tu, Hai-Yan, et al.
Publicado: (2020)

Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations
por: Liang, Wenhua, et al.
Publicado: (2014)

Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population
por: SUTANDYO, Noorwati, et al.
Publicado: (2019)

Drug Resistance to Molecular Targeted Therapy and Its Consequences for Treatment Decisions in Non-Small-Cell Lung Cancer
por: Spaans, Johanna N., et al.
Publicado: (2014)

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
por: Paz-Ares, L., et al.
Publicado: (2017)

Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial
por: Wu, Yi-Long, et al.
Publicado: (2018)

Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity
por: Yamanaka, Yumie, et al.
Publicado: (2017)

EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong – A cost-effectiveness analysis
por: You, Joyce H. S., et al.
Publicado: (2021)

The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non–Small Cell Lung Cancer
por: Jung, Hyun Ae, et al.
Publicado: (2023)

Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial
por: Saran, Frank, et al.
Publicado: (2021)

Targeted Therapies Development in the Treatment of Advanced Nonsmall Cell Lung Cancer
por: Gridelli, Cesare, et al.
Publicado: (2011)

Afatinib in Non–Small Cell Lung Cancer
por: Wirth, Scott M.
Publicado: (2015)

A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies
por: Goss, Glenwood D., et al.
Publicado: (2016)

Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)
por: Felip, Enriqueta, et al.
Publicado: (2008)

Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer
por: Dienstmann, Rodrigo, et al.
Publicado: (2011)

A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing mice
por: Slobbe, Paul, et al.
Publicado: (2015)

The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells
por: Murakami, Yuichi, et al.
Publicado: (2017)

The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer
por: Jung, Hyun Ae, et al.
Publicado: (2020)

Survival analysis of afatinib versus erlotinib for individuals with advanced del19 lung adenocarcinoma with asymptomatic brain metastasis after pemetrexed-cisplatin chemotherapy: a retrospective study
por: Jiang, Ye, et al.
Publicado: (2020)

Erlotinib-Associated Rash in Advanced Non-Small Cell Lung Cancer: Relation to Clinicopathological Characteristics, Treatment Response, and Survival
por: Kainis, Ilias, et al.
Publicado: (2018)

A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196
por: Leighl, Natasha B., et al.
Publicado: (2017)

Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer
por: Lee, Youngjoo, et al.
Publicado: (2017)

Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
por: Arakawa, Nobuhito, et al.
Publicado: (2013)

Combination Erlotinib-Cisplatin and Atg3-Mediated Autophagy in Erlotinib Resistant Lung Cancer
por: Lee, Jasmine G., et al.
Publicado: (2012)

Successful erlotinib rechallenge in an EGFR‐mutant metastatic non‐small cell lung cancer patient with afatinib‐induced drug rash with eosinophilia and systemic symptoms: A case report
por: Lin, Chung‐Fu, et al.
Publicado: (2021)

Overall survival of patients with EGFR mutation-positive non-small-cell lung cancer treated with erlotinib, gefitinib or afatinib under drug programmes in Poland – real-world data
por: Brzozowska, Melania, et al.
Publicado: (2019)

Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study
por: Lee, Suey-Haur, et al.
Publicado: (2022)

Afatinib for the treatment of metastatic non-small cell lung cancer
por: Joshi, Monika, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_kj18274eguv6ep808gc2oauimj